Chemotherapy may modulate PD-L1 expression in malignant pleural mesothelioma (MPM), influencing immune checkpoint inhibitor (ICI) efficacy.
We compared cisplatin (CDDP) and pemetrexed (PEM) on PD-L1 dynamics in MPM.
